Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Arcus) ARC-6A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate CancerHotte, Dr SebastienOpen to recruitmentNCT04381832
(CCTG) BL.13A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder CancerLalani, Dr Aly-KhanOpen to recruitmentNCT03768570
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpen to recruitmentNCT03385655 (Master)
(CCTG) IND.234B/PC-BETS Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(B)
(CCTG) IND.234C/PC-BETS Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(C)
(CCTG) IND.234D/PC-BETS Sub-Study DA Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Mukherjee, Dr SomOpen to recruitmentNCT03385655(D)
(CCTG) IND.234E/PC-BETS Sub-Study EA Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)Mukherjee, Dr SomOpen to recruitmentNCT03385655(E)
(CCTG) IND.234F/PC-BETS Sub-Study FA Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (F)
(CCTG) IND.234G/PC-BETS Sub-Study GA Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (G)
(CCTG) PR.20A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)Quan, Dr KimmenOpen to recruitmentNCT03784755
(CHUM) 20.208 / PATRONPSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate CancerTsakiridis, Dr TheosOpen to recruitmentNCT04557501
(EXELIXIS) XL184-315 / CONTACT-02A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer.Hotte, Dr SebastienOpen to recruitmentNCT04446117
(Immunomedics) TROPICS-04 / IMMU-132-13A RANDOMIZED OPEN-LABEL PHASE III STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED UNRESECTABLE UROTHELIAL CANCERMukherjee, Dr SomOpen to recruitmentNCT04527991
(JCC) The PBS StudyA randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa)Tsakiridis, Dr TheosOpen to recruitmentNCT03380806
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosOpen to recruitmentNCT02685397
(Merck) MK-3475-641 / KEYNOTE 641A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Lalani, Dr Aly-KhanOpen to recruitmentNCT03834493
(OHRI) RADIANT/OTT-19-07/OZM-105Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI 4736) prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)Lalani, Dr Aly-KhanOpen to recruitmentNCT04543110
(Seattle Genetics) SGN22E-003 / EV-302An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus
chemotherapy alone in previously untreated locally advanced
or metastatic urothelial cancer
Hotte, Dr SebastienOpen to recruitmentNCT04223856
(UHN) WI222910 / ALPACAA Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based ChemotherapyMukherjee, Dr SomOpen to recruitmentNCT03391479
OCOG-2019-CYTOSHRINK / CA209-7DRCytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerLalani, Dr Aly-KhanOpen to recruitmentNCT04090710
NRG-GU005 / HYPORTPhase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer.Dayes, Dr IanSuspended/On holdNCT03367702
Download PDF